An observational study in Primary Open Angle Glaucoma (POAG), sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-13.
Sponsored by Sohag University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Glaucoma, Open-Angle with a site in Egypt — 5 open to participants now, 6 under way, none of them phase 3. Glaucoma, Open-Angle · Egypt.
Among the 25 studies in Glaucoma, Open-Angle with a site in Egypt, this one is one of 3 that started in 2026, is one of 8 observational ones, and was the 18th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →5 of the 25 studies in Glaucoma, Open-Angle with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 65–75 · Women only
Cairo University · Sites in Egypt
Ages 30–50
Minia University Hospital · Sites in Egypt
Minia University · Sites in Egypt
Ages 40+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 30 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 3 started in 2026.
This study's planned enrollment of 80 is below the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.
Median enrollment 46 across the 17 interventional studies, 78 across the 8 observational. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 25 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Sohag University has 3 studies filed under Glaucoma, Open-Angle — fewer than ten, so there is no comparison to draw.
3 of the studies in Glaucoma, Open-Angle with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07454447Minia University HospitalUBM Evaluation After Combined Deep Sclerectomy With Trabeculotomy in Primary Open Angle Glaucoma | 2026-11 |
| NCT07599241Cairo UniversityAdditive Efficacy of Physical Activity Program in Hypthyroidism Elder Females With Glaucoma and Fatty Liver Issues | 2026-12-15 |
| NCT07119905Sohag UniversityAssociation Between Matrix Metalloproteinase-9 Gene Polymorphism and Susceptibility to Primary Open Angle Glaucoma Patients in Sohag University Hospital | 2027-01-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Glaucoma, Open-Angle with a site in Egypt, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to investigate the potential association between MMP-9 gene polymorphism and susceptibility to Primary Open Angle Glaucoma development in Egyptian patients The main question it aims to
Glaucoma is the second most common cause of blindness worldwide. Glaucoma is a progressive optic neuropathy, characterized by a specific loss of retinal nerve fibres and ganglion cells, gradual decrease of the visual field, and vertical elongation of optic disc cupping. Glaucoma causes a slow loss of vision in the centre of the field of view as well as in the periphery. This results in delays in the diagnosis and treatment, and it is likely that the glaucoma may not be diagnosed until the disease has progressed to a moderate or severe level, at which point significant vision loss will have already taken place
POAG is the most common type of glaucoma that is characterized by specific glaucomatous retinal, optic nerve, and clinical findings without a clear secondary cause.
POAG is a progressive optic neuropathy characterized by loss of ganglion cells and deterioration of the visual field in eyes with gonioscopically open angles, either with or without increased intraocular pressure (IOP).
Matrix Metalloproteinase-9 gene Matrix metalloproteinases (MMPs) are a kind of calcium-zinc ion-dependent proteolytic enzyme involved in a variety of cellular processes. MMPs are well known for their ability to degrade the extracellular matrix (ECM) and are involved in several intracellular mechanisms from cell differentiation, proliferation, and angiogenesis to apoptosis.
The MMP genes were suggested to play an important role in the development of various glaucoma types, MMPs are important regulators of the aqueous humor outflow from the eye anterior chamber and therefore significantly affect intraocular pressure. Patients with diagnosed POAG have an altered MMPs level in the aqueous humor.
Several studies have been conducted to analyze polymorphic variants of the MMP for their possible contribution to POAG, Several loci of the MMP genes (rs3918242, rs3918249, rs17576 matrix metalloproteinase-9 were associated with POAG.
Patients with Primary Open Angle Glaucoma in Department of ophthalmology in Sohag University Hospitals and healthy controls of matched age and sex
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Normal healthy volunteers aged \> 30 years
Genetic: genotyping assay by polymerase chain reaction
Patients aged \>30 years and diagnosed with Primary Open Angle Glaucoma
Genetic: genotyping assay by polymerase chain reaction
Blood sample will be obtained from all participants by withdrawing 3 mL of blood via venipuncture in ethylenediaminetetraacetic acid tube. Thereafter, DNA extraction will be obtained after centrifugation to be used for genotyping assay of MMP-9 gene with polymerase chain reaction
Matrix metalloproteinase-9 gene polymorphism
Matrix metalloproteinase-9 gene polymorphism by polymerase chain reaction
Time frame: 14 months
Plan to share: Undecided
Start is estimated for Jun 2026; primary completion for Jan 2027, 7 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.